All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @socalurologyinstitute on TikTok · 59s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @socalurologyinstitute's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:01Thanks for this question.
  2. 0:02The gentleman is sharing that he's being treated with 100 milligrams of testosterone
  3. 0:07a week.
  4. 0:08Usually that's a half cc if it's 200 milligrams per cc, but basically 100 milligrams per week.
  5. 0:13100 milligrams per week for most men is a low dose.
  6. 0:18So if you're on 100 milligrams, it's probably not enough.
  7. 0:22If you weigh about 100 pounds and maybe appropriate, if you're pretty lean and most
  8. 0:26people, my size will need between 150 and 200 milligrams.
  9. 0:31Most twice that dose.
  10. 0:32So I can't tell you how many times I hear patients talk about their providers are unwilling
  11. 0:37to go above 100 milligrams.
  12. 0:39And essentially in my opinion, that's substandard testosterone replacement.
  13. 0:45And you need to find a new clinic, a new provider, which is frustrating.
  14. 0:49So you shouldn't have to do that.
  15. 0:51The specialist should know what they're doing.
  16. 0:53But 100 milligrams is too low of a dose, I'm afraid.

TRT claims from a urology account: what holds up?

Dr Gary Bellman | SoCalUrology

TikTok creator

3.2K viewsWatch on TikTok

Quick answer

The video addresses testosterone cypionate dosing at 100mg/week in hypogonadal men and argues this dose is categorically insufficient for most patients. Clinical guidelines from the Endocrine Society specify that TRT dosing should be individualized based on serum testosterone levels, symptom response, and tolerability rather than a fixed milligram threshold. Dismissing 100mg/week as universally inadequate without lab context conflicts with evidence-based titration protocols and may encourage patients to seek higher doses without appropriate clinical oversight.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TRT claims from a urology account: what holds up?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

TRT claims from a urology account: what holds up? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "TRT claims from a urology account: what holds up?" from Dr Gary Bellman | SoCalUrology. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video addresses testosterone cypionate dosing at 100mg/week in hypogonadal men and argues this dose is categorically insufficient for most patients.

The reason this review is not generic is the source wording and the canonical claim label "trt replying to wallace." In this clip, the useful excerpt is: "Thanks for this question." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Ramasamy et al.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video addresses testosterone cypionate dosing at 100mg/week in hypogonadal men and argues this dose is categorically insufficient for most patients.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video addresses testosterone cypionate dosing at 100mg/week in hypogonadal men and argues this dose is categorically insufficient for most patients. Clinical guidelines from the Endocrine Society specify that TRT dosing should be individualized based on serum testosterone levels, symptom response, and tolerability rather than a fixed milligram threshold. Dismissing 100mg/week as universally inadequate without lab context conflicts with evidence-based titration protocols and may encourage patients to seek higher doses without appropriate clinical oversight.
  • The Endocrine Society (Bhasin et al., 2018) recommends targeting serum testosterone to mid-normal physiological ranges, typically 400-700 ng/dL, not a specific weekly milligram dose.
  • Ramasamy et al. (2019, Translational Andrology and Urology) confirmed that testosterone metabolism varies significantly between individuals due to SHBG levels, body composition, and injection frequency.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The Endocrine Society (Bhasin et al., 2018) recommends targeting serum testosterone to mid-normal physiological ranges, typically 400-700 ng/dL, not a specific weekly milligram dose.
  • Ramasamy et al. (2019, Translational Andrology and Urology) confirmed that testosterone metabolism varies significantly between individuals due to SHBG levels, body composition, and injection frequency.
  • Some men on 100mg/week of testosterone cypionate achieve fully therapeutic serum levels. Others do not. The bloodwork is what matters, not the dose number alone.
  • Supraphysiological testosterone dosing carries documented risks including erythrocytosis, elevated hematocrit, and fertility suppression (Jones et al., 2011, Clinical Endocrinology).
  • FDA prescribing information for testosterone cypionate lists 50-100mg every one to two weeks as a standard starting range, with titration based on lab results.
  • Providers who decline to increase testosterone dose when labs are already in the therapeutic range are following evidence-based protocols, not practicing substandard medicine.
  • If you are symptomatic on 100mg/week, ask your provider to review your trough and peak testosterone levels before any dose change is considered.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @socalurologyinstitute actually say?

The creator, presenting as a urologist, told a patient asking about his 100mg/week testosterone protocol that this dose is almost universally insufficient. His words: "100 milligrams per week for most men is a low dose" and "100 milligrams is too low of a dose, I'm afraid." He went further, calling providers unwilling to exceed 100mg/week guilty of "substandard testosterone replacement" and advising patients to find new clinics. He did carve out a narrow exception for very light or lean individuals, but the overall message was unambiguous: 100mg is inadequate for most men, and the providers prescribing it don't know what they're doing.

Does the science back this up?

Partially, but the blanket dismissal of 100mg/week oversimplifies how testosterone therapy actually works. The Endocrine Society's 2018 clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) recommend titrating testosterone to mid-normal physiological ranges, typically 400-700 ng/dL mid-cycle. What dose achieves that varies considerably by individual. For some men, 100mg/week of testosterone cypionate is enough to reach mid-normal levels. For others, it is not. Declaring the dose universally inadequate without knowing a patient's labs ignores that basic pharmacokinetic reality.

A 2019 analysis by Ramasamy et al. in Translational Andrology and Urology confirmed significant inter-individual variability in testosterone metabolism. Body composition, SHBG levels, injection frequency, and androgen receptor sensitivity all influence response. Treating 100mg as a categorical failure ignores this variability entirely.

What did they get wrong, and what did they get right?

Credit where it is due: the creator is right that some providers are overly conservative and that under-treated hypogonadism is a real clinical problem. Studies like Khera et al. (2016, Journal of Sexual Medicine) document that many men with symptomatic hypogonadism receive inadequate monitoring or dosing adjustments. That frustration is legitimate.

But calling 100mg categorically "substandard" is where this video goes wrong. Dose adequacy is determined by lab values and symptom resolution, not by the number on the syringe. A man on 100mg/week whose total testosterone sits at 650 ng/dL mid-cycle and who feels well is not being undertreated. The creator's framing, that any provider who prescribes 100mg lacks competence, risks pushing patients toward higher doses they may not need. That carries real consequences: erythrocytosis, elevated hematocrit, and suppressed fertility are all documented risks of supraphysiological dosing (Jones et al., 2011, Clinical Endocrinology).

What should you actually know?

TRT dosing is not one-size-fits-all, and no video can determine what your dose should be. The standard of care requires lab-guided titration, not a milligram target assumed before bloodwork is reviewed.

The FDA-approved starting dose for testosterone cypionate in hypogonadal men is typically 50-100mg every one to two weeks, with adjustments based on serum testosterone levels (FDA prescribing information, Depo-Testosterone). Many men on weekly injection protocols land in the 100-150mg range and achieve optimal levels. Some need more. The difference is found in the bloodwork, not assumed in advance.

If you are on 100mg/week and still symptomatic, that is a valid conversation to have with your provider, backed by trough and peak labs. But if your numbers are in range and you feel well, no TikTok video should convince you that your care is substandard. Ask your provider to walk you through your testosterone levels before changing anything.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr Gary Bellman | SoCalUrology · TikTok creator

3.2K views on this video

Replying to @Wallace

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the endocrine society (bhasin et al., 2018) recommends targeting serum?

The Endocrine Society (Bhasin et al., 2018) recommends targeting serum testosterone to mid-normal physiological ranges, typically 400-700 ng/dL, not a specific weekly milligram dose.

What does the video say about ramasamy et al. (2019, translational andrology?

Ramasamy et al. (2019, Translational Andrology and Urology) confirmed that testosterone metabolism varies significantly between individuals due to SHBG levels, body composition, and injection frequency.

What does the video say about some men on 100mg/week of testosterone cypionate achieve fully therapeutic?

Some men on 100mg/week of testosterone cypionate achieve fully therapeutic serum levels. Others do not. The bloodwork is what matters, not the dose number alone.

What does the video say about supraphysiological testosterone dosing carries documented risks including erythrocytosis, elevated hematocrit,?

Supraphysiological testosterone dosing carries documented risks including erythrocytosis, elevated hematocrit, and fertility suppression (Jones et al., 2011, Clinical Endocrinology).

What does the video say about fda prescribing information for testosterone cypionate lists 50-100mg every one?

FDA prescribing information for testosterone cypionate lists 50-100mg every one to two weeks as a standard starting range, with titration based on lab results.

What does the video say about providers who decline to increase testosterone dose?

Providers who decline to increase testosterone dose when labs are already in the therapeutic range are following evidence-based protocols, not practicing substandard medicine.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by Dr Gary Bellman | SoCalUrology, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.